This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Discussing how access and pricing are being considered for Zurzuvae (zuranolone).
Ticker(s): SAGEWho's the expert?
Institution: Schwarck Healthcare Reimbursement
- Experienced healthcare finance consultant who is available for short and long-term healthcare reimbursement support. Specializing in new drug launch reimbursement support, medical device and technology finance, field representative ongoing support services, hub access support and education, specialty drug reimbursement, denials appeals, pre-authorizations, radiation and medical oncology reimbursement, complex reimbursement issues, request for proposal assistance, clinical trials reimbursement, project deadline support, coding solutions, education, training, market access, healthcare investment analysis, medical policy navigation, and process improvements.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
